Biogen gene therapy expert latest to join TxCell's advisory board

25 August 2016
2019_biotech_test_vial_discovery_big

French biotech TxCell (Euronext Paris: TXCL) has appointed Oliver Danos to its Scientific Advisory Board (SAB).

Dr Danos is senior vice president of cell and gene therapy at US biotech major Biogen (Nasdaq: BIIB) and is seen as a world-leading expert in the field of gene therapy for hematological and neurological diseases.

TxCell, which is focused on developing personalized cellular immunotherapies using regulatory T cells (Treg) to treat severe chronic inflammatory and autoimmune diseases, now has an SAB comprising of four world-leading immunology experts.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology